Gliatech (GLIA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1413)	3/1/2000 3:29:00 PM
From: Dr. John M. de Castro	Read Replies (1) of 2001

I get the distinct impression that GLIA management put together this nice conservative business plan when biotech was trash to Wall Street. They are now stubbornly sticking to the plan and haven't noticed that the Universe has changed. Would someone send them a list of current biotech company market valuations? I like the idea that GLIA is not dilluting its stock. But, the money could be used to fund clinical trials and gain them far more than they invest in the terms of the eventual marketing arrangement. They talked of partnering Perceptin based upon the preclinical and PI data. IMHO they would get a lousy deal from a Pharma under these conditions. They'd probably have to take mid single digit royalties to partner with this level of data. But, with complete and significant Phase IIa and IIb data, it would be an entirely different ballgame. It would be money, and dillution, very well spent. Best regards John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next